Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR91 | A4D1P6 | 4/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879488 | 0.82 | WDR91 (0.50) | WDR91CXCR3FAAHRAB9ACCR1 | |
| SCHEMBL27995135 | 0.74 | WDR91 (0.45) | WDR91CXCR3FAAHCCR1 | |
| SCHEMBL16249346 | 0.73 | WDR91 (0.53) | WDR91CXCR3CCR1 | |
| SCHEMBL14879817 | 0.72 | WDR91 (0.41) | WDR91CXCR3FAAHCCR1 | |
| SCHEMBL16309650 | 0.67 | MGLL (0.50) | PKMRAB9A | |
| SCHEMBL10207451 | 0.67 | MGLL (0.50) | PKMRAB9A | |
| SCHEMBL28545624 | 0.66 | NPC1 (0.50) | WDR91CXCR3RAB9ACCR1 | |
| SCHEMBL14879829 | 0.65 | OPRM1 (0.42) | OPRM1OPRL1PKMRAB9A | |
| SCHEMBL10207447 | 0.64 | PKM (0.37) | PKMRAB9A | |
| SCHEMBL16309692 | 0.64 | PKM (0.37) | PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9266908-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| EP-2768491-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | WDR91 975/4885CXCR3 1039/4885OPRM1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.